📰 U.S. approves two Injective ETF applications: Why are crypto funds making a move now?
U.S. regulators recently approved two ETF applications related to Injective Chain, directly pushing up the price of INJ. For the broader crypto market, this means another compliant investment channel is now available, potentially attracting more traditional capital in the future. Injective Chain is focused on decentralized derivatives trading, and approval of an ETF in this area suggests regulators are gradually opening up to specific crypto application sectors, giving the entire industry a boost.
Why is this news important?
This ETF approval is not an isolated event, but a sign of a gradual shift in regulatory attitudes. Injective Chain occupies a very distinctive position in crypto: it focuses on the decentralized derivatives market, an area traditional finance is eager to enter but finds difficult to navigate. The U.S. approval of an ETF tied to this kind of innovative application shows that, building on a "regulatory sandbox" approach, regulators are beginning to explore standardized tools to address specific industry pain points. Why approve it now? On the one hand, sluggish market sentiment needs a positive catalyst; on the other, decentralized derivatives have a two-year track record, the technology is relatively mature, and the risks are more manageable.
Impact on the market
The impact on BTC and ETH is mostly sentiment-driven. ETH at $2,720.22 has performed strongly recently, mainly benefiting from a recovery in the L2 network ecosystem, while the ETF news offers it limited direct support. But as a market bellwether, ETF approval means that more similar products may be approved in the future, changing the crypto investment landscape—capital can invest directly in specific sectors through compliant channels. Historically, after each round of ETF approvals, the market has seen a 3–6 month window of capital inflows, and this time should be no exception. A possible transmission path is: ETF capital enters the INJ token through traditional channels, and some of it then spills over into BTC and ETH, the market's cornerstone assets.
💡 Personal view: The U.S. approval of an Injective ETF may boost INJ in the short term, but the signal truly worth watching is the transparency of ETF holdings. If INJ ETF holdings remain above 50,000 tokens over the next month (the current circulating supply is about 1.2 million), that would mean compliant capital is starting to position itself in the Injective ecosystem—and only then would this feed into the long-term trend for BTC at $86,240. If capital flows in but the INJ price stagnates, it would suggest investors value the ETF itself more than the underlying chain, invalidating this thesis.
This article is not sponsored by any project, and the author does not hold any of the assets mentioned.
Source: CryptoBriefing ⚠️ This is not investment advice. Forecasts are for reference only.
#SpotETFInflows
U.S. regulators recently approved two ETF applications related to Injective Chain, directly pushing up the price of INJ. For the broader crypto market, this means another compliant investment channel is now available, potentially attracting more traditional capital in the future. Injective Chain is focused on decentralized derivatives trading, and approval of an ETF in this area suggests regulators are gradually opening up to specific crypto application sectors, giving the entire industry a boost.
Why is this news important?
This ETF approval is not an isolated event, but a sign of a gradual shift in regulatory attitudes. Injective Chain occupies a very distinctive position in crypto: it focuses on the decentralized derivatives market, an area traditional finance is eager to enter but finds difficult to navigate. The U.S. approval of an ETF tied to this kind of innovative application shows that, building on a "regulatory sandbox" approach, regulators are beginning to explore standardized tools to address specific industry pain points. Why approve it now? On the one hand, sluggish market sentiment needs a positive catalyst; on the other, decentralized derivatives have a two-year track record, the technology is relatively mature, and the risks are more manageable.
Impact on the market
The impact on BTC and ETH is mostly sentiment-driven. ETH at $2,720.22 has performed strongly recently, mainly benefiting from a recovery in the L2 network ecosystem, while the ETF news offers it limited direct support. But as a market bellwether, ETF approval means that more similar products may be approved in the future, changing the crypto investment landscape—capital can invest directly in specific sectors through compliant channels. Historically, after each round of ETF approvals, the market has seen a 3–6 month window of capital inflows, and this time should be no exception. A possible transmission path is: ETF capital enters the INJ token through traditional channels, and some of it then spills over into BTC and ETH, the market's cornerstone assets.
💡 Personal view: The U.S. approval of an Injective ETF may boost INJ in the short term, but the signal truly worth watching is the transparency of ETF holdings. If INJ ETF holdings remain above 50,000 tokens over the next month (the current circulating supply is about 1.2 million), that would mean compliant capital is starting to position itself in the Injective ecosystem—and only then would this feed into the long-term trend for BTC at $86,240. If capital flows in but the INJ price stagnates, it would suggest investors value the ETF itself more than the underlying chain, invalidating this thesis.
This article is not sponsored by any project, and the author does not hold any of the assets mentioned.
Source: CryptoBriefing ⚠️ This is not investment advice. Forecasts are for reference only.
#SpotETFInflows
